Drug intelligence / Profile preview

QRX004

Development stage: Discontinued
Lead developer: Quoin Pharmaceuticals
Modality: Small Molecules
Administration: Unknown

Overview

QRX004 is a **small molecule drug** developed by Quoin Pharmaceuticals as a potential therapy for Epidermolysis Bullosa, a rare genetic skin disorder. Its proposed mechanisms include modulation of **collagen** and inhibition of **serine protease** activity, targeting pathways implicated in skin structure and inflammatory processes. QRX004 was positioned for the treatment of rare dermatological conditions but its development has since been discontinued[1][2][5].

Other names: QRX004QRX-004QRX 004

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on QRX004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRX004.

Explore the full profile